Prospective phase Ⅱ study of postoperative concurrent chemoradiotherapy for patients with high-risk malignant salivary gland tumors
10.3760/cma.j.issn.1004-4221.2020.03.002
- VernacularTitle:高危唾液腺肿瘤患者术后同期放化疗前瞻性Ⅱ期临床试验研究
- Author:
Xin WANG
1
;
Shengjin DOU
;
Rongrong LI
;
Sicheng WU
;
Gang CHEN
;
Lin ZHANG
;
Wenjun YANG
;
Guopei ZHU
Author Information
1. 上海交通大学医学院附属第九人民医院黄浦分院放疗科 200011
- Keywords:
High-risk salivary gland tumor;
Postoperative adjuvant;
Concurrent chemoradiotherapy;
Prospective study
- From:
Chinese Journal of Radiation Oncology
2020;29(3):166-170
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the efficacy and safety of post operative adjuvant concurrent chemoradiotherapy for patients with high-risk salivary gland tumors (SGT).Methods Fifty-two patients with moderate or high malignant pathological stage complicated with locally advanced stage Ⅲ/ⅣA±positive margin/close margin admitted to Shanghai Ninth People's Hospital from 2016 to 2018 were enrolled in this study.Among them,35 patients were male and 17 female with a median age of 55.5 years old (range:21-73 years old).All 52 patients were treated with intensity-modulated radiotherapy and concurrent chemotherapy.Patients with adeno carcinoma of the salivary gland receives concurrent chemotherapy with TP regimen.Patients with lympho epithelial cancer and squamous cell carcinoma were treated with cisplatin regimen.Results Forty-seven patients (90％) completed two cycles of concurrent chemotherapy,and five patients (10％) completed one cycle of concurrent chemotherapy.The median follow-up time was 15.7 months (3.2-34.8 months).The 2-year disease-free survival (DFS) and overall survival (OS) rates were 74％ and 98％.Three patients experienced regional lymph recurrence and 6 cases had distant metastasis.Grade Ⅲ oral mucositis was observed in 30 patients.Grade Ⅲ dermatitis occurred in 5 cases.Only one patient experienced Grade Ⅳ neutropenia,and 2 patients developed Grade Ⅲ neutropenia.DFS was positively correlated with the cycle of postoperative adjuvant concurrent chemotherapy (P=0.006).Conclusions Patients with high-risk SGT can obtain higher 2-year DFS and OS rates and tolerable adverse events after postoperative concurrent chemoradiotherapy.Nevertheless,the long-term outcomes remain to be validated by randomized controlled clinical trials.
